An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
This bill aims to improve access to biomarker testing for cancer patients in Massachusetts to help them receive the most appropriate therapy. It requires health insurers to cover the cost of these specific tests without imposing additional restrictions or requiring prior authorization beyond what is already standard for other medical services. The legislation directly affects cancer patients, their families, and health insurance providers by ensuring that necessary diagnostic tools are financially accessible. By removing barriers to testing, the bill seeks to facilitate better treatment decisions based on individual patient biology.
Bill status
passed
3 of 4 stages cleared
Introduction
Feb 2023
Committee Review
Jun 2024
Senate Passage
Mar 2024
Governor
Introduced Feb 16, 2023
Last action Jun 20, 2024
Floor votes
How they voted
This bill passed the Senate. No roll call record of that vote is available.
Full legislative history
Actions timeline
Total actions
9
Key actions
2
Committee
3
Jun 20, 2024
Committee
Committee recommended bill ought to pass and referred to the committee on House Ways and Means
lower
May 23, 2024
Committee
Reported favorably by committee and referred to the committee on Health Care Financing
lower
Mar 28, 2024
Upper · Passed
Senate concurred
upper
Feb 16, 2023
Upper · Passed
Senate concurred
upper
Feb 16, 2023
Committee
Referred to the committee on Financial Services
lower
0 primary · 77 co-sponsors
Sponsors
No sponsor information available.
Ask Maddy
·
AI policy assistant
Ask Maddy about H 1074
Scope: MA
Hi! I can help you understand H 1074. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline